Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;37(8):10.1002/gps.5789.
doi: 10.1002/gps.5789.

Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria

Zara Togher  1 , Helena Dolphin  2 , Caoimh Russell  1 , Marie Ryan  1 , Séan P Kennelly  2 , Séan O'Dowd  1   2
Affiliations

Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria

Zara Togher et al. Int J Geriatr Psychiatry. 2022 Aug.

Abstract

Objectives: Aducanumab is a monoclonal antibody which has recently been licenced for use by the food and drug administration for treatment of patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia. Appropriate use criteria (AUC) for Aducanumab in clinical practice are available. We look to review patients in our specialist interdisciplinary cognitive service with positive cerebrospinal fluid (CSF) biomarkers for AD for their hypothetical eligibility for Aducanumab, or a similar anti-amyloid agent.

Methods: Retrospective analysis was undertaken of patients with positive AD-biomarker CSF analysis. Data available at time of CSF analysis was reviewed to determine hypothetical eligibility for Aducanumab.

Results: Seventy patients had positive AD-CSF biomarkers. Forty nine of these were seen in the Gerontology-led service, with 21 in the neurology cohort. Average patient age was 70 years old. Forty patients (57%) met eligibility criteria for Aducanumab therapy by AUC guidelines.

Conclusion: We highlight the patients within our service who would be appropriate for Aducanumab or similar anti-amyloid agents should licencing be granted in the European Union, and the need to develop the resources and capacity to deliver this or other emerging disease modifying AD therapies.

Clinical trial registration: All patients in the combined cognitive clinic provide consent re willingness to be contacted re research.

Keywords: Aducanumab; Alzheimer's; anti-amyloid therapy; cognition; memory.

PubMed Disclaimer

Conflict of interest statement

The author declares that they have no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Full outcomes of those unsuitable for Aducanumab therapy
See this image and copyright information in PMC

References

    1. Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer disease. 2021 Aug 11. In: StatPearls [Internet]. StatPearls Publishing; 2021. PMID: 29763097.
    1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011;377(9770):1019‐1031. Epub 2011 Mar 1. PMID: 21371747. 10.1016/S0140-6736(10)61349-9 - DOI - PubMed
    1. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the international working group. Lancet Neurol. 2021;20(6):484‐496. Epub 2021 Apr 29. PMID: 33933186; PMCID: PMC8339877. 10.1016/S1474-4422(21)00066-1 - DOI - PMC - PubMed
    1. Murphy MP, LeVine H, 3rd . Alzheimer's disease and the amyloid‐beta peptide. J Alzheim Dis. 2010;19(1):311‐323. 10.3233/JAD-2010-1221 - DOI - PMC - PubMed
    1. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener. 2019;14(1):32. PMID: 31375134; PMCID: PMC6679484. 10.1186/s13024-019-0333-5 - DOI - PMC - PubMed

Publication types

MeSH terms